The Tipster | Astrazeneca takes its medicine
INVESTORS are eagerly waiting to hear from AstraZeneca’s new chief executive, when the company reports on Thursday. The new boss has the challenge of reinvigorating the pharma giant after recent investor frustration, and has already shuffled the boardroom. As well as headline numbers, traders will be focusing on the company’s strategy to boost its pipeline of drugs. ETX Capital quotes a price of 3142.5p-3148.5p.
Rumours of a takeover have sent shares in United Utilities Group streaming higher, adding 10 per cent in January. The company has made significant operational improvements recently, and looks cheaper than some of its peers. Eyes will be on tomorrow’s management statement, which may jolt potential suitors into putting their cash on the table. Capital Spreads quotes a price of 741.10p-742.40p.